Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Receivables - Other for 5 consecutive years, with $488372.0 as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 24064.87% to $488372.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $488372.0 through Dec 2025, up 24064.87% year-over-year, with the annual reading at $237.0 for FY2025, N/A changed from the prior year.
- Receivables - Other for Q4 2025 was $488372.0 at Neuphoria Therapeutics, up from $1758.0 in the prior quarter.
- The five-year high for Receivables - Other was $4.8 million in Q2 2022, with the low at $237.0 in Q2 2025.
- Average Receivables - Other over 4 years is $663789.5, with a median of $1889.5 recorded in 2024.
- The sharpest move saw Receivables - Other plummeted 99.99% in 2023, then surged 24064.87% in 2025.
- Over 4 years, Receivables - Other stood at $4.8 million in 2022, then tumbled by 99.99% to $592.17 in 2023, then surged by 241.29% to $2021.0 in 2024, then soared by 24064.87% to $488372.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $488372.0, $1758.0, and $237.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.